Cogent Biosciences’ Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial

All NewsNovember 10, 2025

Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIST trial.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent